Safety Shot (NASDAQ:SHOT - Get Free Report) issued its earnings results on Thursday, August 14th. The company reported ($0.03) earnings per share for the quarter, Zacks reports. The company had revenue of $0.45 million during the quarter.
Safety Shot Stock Down 2.8%
Shares of SHOT stock traded down $0.0137 during midday trading on Thursday, reaching $0.4727. 3,508,349 shares of the stock were exchanged, compared to its average volume of 10,403,774. Safety Shot has a 1 year low of $0.23 and a 1 year high of $1.77. The company's 50 day moving average is $0.55 and its two-hundred day moving average is $0.48.
Analysts Set New Price Targets
Separately, Wall Street Zen upgraded Safety Shot from a "sell" rating to a "hold" rating in a report on Saturday, August 16th.
Get Our Latest Research Report on SHOT
Safety Shot Company Profile
(
Get Free Report)
Safety Shot, Inc, a wellness and functional beverage company, researches and develops over-the-counter products and intellectual property. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It also develops Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women's sexual wellness; and NoStingz, a jellyfish sting prevention sunscreen.
Read More

Before you consider Safety Shot, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Safety Shot wasn't on the list.
While Safety Shot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.